Adverse Events and Measurement of Dissociation After the First Dose of Esketamine in Patients With TRD
International Journal of Neuropsychopharmacology · 22.03.2023 · 26 (3) · 198-206
DOI: 10.1093/ijnp/pyac081 ↗Kurz gefasst
Klinische Studie in der Zeitschrift International Journal of Neuropsychopharmacology, online erschienen am 16.12.2022. Verfasst von David Williamson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA. Hauptthemen laut MEDLINE: Depressive Disorder, Treatment-Resistant, Ketamine, Psychotic Disorders. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Background “Dissociation” comprises distinct phenomena, some of which are associated with esketamine treatment and some may overlap with positive symptoms of psychosis. Relationships between dissociation and psychotic symptoms assessed by clinician report vs conventional rating scales were investigated in a post hoc analysis of data from the initial treatment session in an open-label, long-term safety, phase 3 study of esketamine plus a newly initiated oral antidepressant in patients with treatment-resistant depression.
Methods
Adverse events of dissociation or psychosis were examined via investigator report and the Clinician Administered Dissociative States Scale (CADSS) and Brief Psychiatric Rating Scale-Plus, respectively, 40 minutes post first esketamine dose. The range of CADSS total scores associated with investigator-reported severity of dissociation was determined by equipercentile linking. Logistic regression models and receiver operating curve analysis explored the CADSS cutoff point for determining presence/absence of dissociation. Frequency of response to specific CADSS items was examined to investigate qualitative differences in the pattern of symptoms reported across investigator-reported levels of adverse event severity.
Results
Dissociation was reported as an adverse event in 14.3% (109/764) of patients. Severity of most CADSS items increased with the severity of investigator-reported dissociation. No CADSS cutoff point discriminated well between the presence and absence of dissociation events. Hallucinations were reported as adverse events in 5 patients; none reported delusions.
Conclusions
CADSS scores and severity of dissociation adverse events move generally in the same direction; however, there is substantial variability in this relationship. No signature profile of dissociative experiences was revealed, and psychotic symptoms were uncommon. Trial Registration Clinical Trials.gov identifier: NCT02497287
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA.
- Department of Psychiatry and Health Behavior at Augusta University, Augusta, Georgia, USA.
- Department of Statistics and Decision Sciences, Janssen Research & Development, LLC, Titusville, New Jersey, USA.
- Department of Neuroscience, Janssen Research & Development Belgium, Beerse, Belgium.
- Neurocrine Biosciences, San Diego, California, USA.
- Department of Neuroscience, Janssen Research & Development, LLC, San Diego, California, USA.
Zitieren
APA
Williamson, D., Turkoz, I., Wajs, E., Singh, J. B., Borentain, S., & Drevets, W. C. (2023). Adverse Events and Measurement of Dissociation After the First Dose of Esketamine in Patients With TRD. International Journal of Neuropsychopharmacology, 26(3), 198-206. https://doi.org/10.1093/ijnp/pyac081
Vancouver
Williamson D, Turkoz I, Wajs E, Singh JB, Borentain S, Drevets WC. Adverse Events and Measurement of Dissociation After the First Dose of Esketamine in Patients With TRD. International Journal of Neuropsychopharmacology. 2023;26(3):198-206. doi:10.1093/ijnp/pyac081
BibTeX
@article{Williamson2023,
author = {Williamson, David and Turkoz, Ibrahim and Wajs, Ewa and Singh, Jaskaran B and Borentain, Stephane and Drevets, Wayne C},
title = {Adverse Events and Measurement of Dissociation After the First Dose of Esketamine in Patients With TRD},
journal = {International Journal of Neuropsychopharmacology},
year = {2023},
volume = {26},
number = {3},
pages = {198--206},
doi = {10.1093/ijnp/pyac081}
}
EUVIMED